JP2021500918A5 - - Google Patents

Info

Publication number
JP2021500918A5
JP2021500918A5 JP2020530435A JP2020530435A JP2021500918A5 JP 2021500918 A5 JP2021500918 A5 JP 2021500918A5 JP 2020530435 A JP2020530435 A JP 2020530435A JP 2020530435 A JP2020530435 A JP 2020530435A JP 2021500918 A5 JP2021500918 A5 JP 2021500918A5
Authority
JP
Japan
Prior art keywords
human
cells
mouse
immunodeficient
test substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020530435A
Other languages
English (en)
Japanese (ja)
Other versions
JP7404237B2 (ja
JP2021500918A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/046021 external-priority patent/WO2019032836A1/en
Publication of JP2021500918A publication Critical patent/JP2021500918A/ja
Publication of JP2021500918A5 publication Critical patent/JP2021500918A5/ja
Application granted granted Critical
Publication of JP7404237B2 publication Critical patent/JP7404237B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020530435A 2017-08-09 2018-08-09 ヒトインターロイキン15を発現する免疫不全マウス Active JP7404237B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762543218P 2017-08-09 2017-08-09
US62/543,218 2017-08-09
US201762554818P 2017-09-06 2017-09-06
US62/554,818 2017-09-06
PCT/US2018/046021 WO2019032836A1 (en) 2017-08-09 2018-08-09 IMMUNODEFICIENT MOUSE EXPRESSING THE HUMAN INTERLEUKINE 15

Publications (3)

Publication Number Publication Date
JP2021500918A JP2021500918A (ja) 2021-01-14
JP2021500918A5 true JP2021500918A5 (cg-RX-API-DMAC7.html) 2023-11-13
JP7404237B2 JP7404237B2 (ja) 2023-12-25

Family

ID=63557672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020530435A Active JP7404237B2 (ja) 2017-08-09 2018-08-09 ヒトインターロイキン15を発現する免疫不全マウス

Country Status (10)

Country Link
US (1) US20200236916A1 (cg-RX-API-DMAC7.html)
EP (1) EP3664603B1 (cg-RX-API-DMAC7.html)
JP (1) JP7404237B2 (cg-RX-API-DMAC7.html)
KR (1) KR102693739B1 (cg-RX-API-DMAC7.html)
CN (2) CN112118734A (cg-RX-API-DMAC7.html)
AU (1) AU2018313892B2 (cg-RX-API-DMAC7.html)
CA (1) CA3072331A1 (cg-RX-API-DMAC7.html)
IL (1) IL272475B2 (cg-RX-API-DMAC7.html)
SG (1) SG11202001109PA (cg-RX-API-DMAC7.html)
WO (1) WO2019032836A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102546A1 (en) 2016-11-30 2018-06-07 The Jackson Laboratory Humanized mouse model with improved human innate immune cell development
WO2021150936A1 (en) * 2020-01-22 2021-07-29 City Of Hope Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer
WO2021159035A1 (en) 2020-02-07 2021-08-12 City Of Hope Oncolytic virus compositions and methods for the treatment of cancer
CN111485001A (zh) * 2020-04-14 2020-08-04 澎立生物医药技术(上海)有限公司 具有nk细胞及adcc能力的人源化免疫系统小鼠的构建方法
CN114304065A (zh) * 2021-12-31 2022-04-12 江苏大学 一种阻断il-8联合抗pd-1抗体治疗胃癌的动物模型构建及应用
WO2024029561A1 (ja) * 2022-08-02 2024-02-08 学校法人東海大学 担がん-免疫不全非ヒト動物、これを用いた供試物質に関するがん免疫応答評価方法
AU2023338373A1 (en) * 2022-09-08 2025-04-03 The Jackson Laboratory Humanized immunodeficient mouse models

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
JP6492095B2 (ja) * 2013-10-15 2019-03-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. ヒト化il−15動物
US20150282460A1 (en) * 2014-04-04 2015-10-08 Crown Bioscience Inc. (Taicang) Animal model with human immune system
ES2950399T3 (es) * 2015-04-13 2023-10-09 Regeneron Pharma Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos
JP6654001B2 (ja) * 2015-05-27 2020-02-26 公益財団法人実験動物中央研究所 ヒトil−15分泌免疫不全マウス
TWI810145B (zh) * 2015-06-23 2023-08-01 杰克森實驗室 具有病患衍生之異種移植物之非hla配對的人源化nsg小鼠模式

Similar Documents

Publication Publication Date Title
Lawal et al. The immunology of hepatocellular carcinoma
Chen et al. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
Munir et al. Classical Hodgkin lymphoma: from past to future—a comprehensive review of pathophysiology and therapeutic advances
Papait et al. Mesenchymal stromal cells from fetal and maternal placenta possess key similarities and differences: potential implications for their applications in regenerative medicine
Zhang et al. PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy
Shaver et al. Natural killer cells: the linchpin for successful cancer immunotherapy
Airoldi et al. γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ+/CD19+ lymphocytes
Tang et al. Molecular mechanisms of low dose ionizing radiation-induced hormesis, adaptive responses, radioresistance, bystander effects, and genomic instability
Pollyea et al. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials
Wang et al. Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer
Ahmed et al. CD57+ memory T cells proliferate in vivo
Chen et al. TIGIT blockade exerts synergistic effects on microwave ablation against cancer
Rao et al. Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies
Bascuas et al. Salmonella immunotherapy improves the outcome of CHOP chemotherapy in non-Hodgkin lymphoma-bearing mice
Caldemeyer et al. Donor lymphocyte infusions used to treat mixed-chimeric and high-risk patient populations in the relapsed and nonrelapsed settings after allogeneic transplantation for hematologic malignancies are associated with high five-year survival if persistent full donor chimerism is obtained or maintained
Bigler et al. Stress-induced in vivo recruitment of human cytotoxic natural killer cells favors subsets with distinct receptor profiles and associates with increased epinephrine levels
Ali et al. The role of anti-thymocyte globulin or alemtuzumab-based serotherapy in the prophylaxis and management of graft-versus-host disease
Bernasconi et al. Immune escape after hematopoietic stem cell transplantation (HSCT): from mechanisms to novel therapies
Lake et al. Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma
Bachiller et al. Natural killer cells in immunotherapy: are we nearly there?
Braun et al. Immunotherapy in myeloproliferative diseases
Kariminia et al. CD56bright natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-versus-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results
Williams et al. CD16+ NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice
Barough et al. Gemcitabine‐loaded injectable hydrogel for localized breast cancer immunotherapy
Gramatica et al. EZH2 inhibition mitigates HIV immune evasion, reduces reservoir formation, and promotes skewing of CD8+ T cells toward less-exhausted phenotypes